Sitemap - 2025 - MS-Selfie
Q&A 98: male sexual dysfunction in MS
Q&A 96: skin rejuvenation therapy and MS
Q&A 95: I live in Scotland should I have AHSCT done privately?
Q&A 94: rebound on switching from fingolimod to cladribine
Type 1 diabetes prevention: lessons for MS
Infectious mononucleosis - a pragmatic target for preventing multiple sclerosis
NOBEL SYMPOSIUM™ Multiple Sclerosis: Past, Present and Future Treatments
HPV vaccination to prevent reinfection
Q&A 93: severe fatigue after switching from ocrelizumab to ofatumumab
Q&A 92: shingles on ocrelizumab
National Early Inflammatory MS Audit
Q&A 90: Ocrelizumab wearing-off phenomenon
Vidofludimus - a Slam Dunk, or not?
Errors in your medical records
Q&A 88: Estriol vs. Estradiol as an HRT for brain health
Q&A 87: worsening hand function in MS
Poverty and socioeconomic deprivation and multiple sclerosis
Q&A 86: STRATIFY-JCV (Tysabri) versus ImmunoWell (Tyruko)
Do you know your QRISK3 score?
Q&A 85: RIS or RRMS? What about PPMS?
Dengue fever and exotic infections
Q&A 83: cladribine vs. siponimod vs. tolebrutinib for smouldering MS
Challenging the dogma around the focal MS lesion
Q&A 82: dopamine agonists for restless legs syndrome - a no-no
Q&A 81: Low JCV-index positive: should I switch to an anti-CD20 therapy or not?
Do you know how to measure your blood pressure?
Q&A 80: Ivermectin as a treatment for multiple sclerosis
ACTRIMS 2025: How old is your brain?
Q&A: Siponimod drug interactions
Q&A 78: ocrelizumab or anti-CD20 therapies and measles
Q&A 77: stopping DMTs due to age
Survey results: AI large language models and MS care
Q&A 75: Natalizumab to tolebrutinib switch
MS self-management - an NHS pipe-dream
Q&A 74: AHSCT with ATG vs AHSCT with rituximab vs alemtuzumab
Q&A 73: Ocrelizumab vs. Ofatumumab vs. Ublituximab
How chubby were you as a child?
Rising incidence of MS in women: what is the telling us about the cause of MS?
TikTok - what it has to tell us about the medical lexicon?
Q&A 72: Smouldering MS: siponimod or cladribine?
Q&A 71: Failing natalizumab - ocrelizumab or AHSCT?
NHS in crisis: we need your help
Preventing multiple sclerosis by vaccination
Q&A 70: Stay on ocrelizumab or switch to alemtuzumab or AHSCT?
Q&A 69: Inflammatory bowel disease and MS
Q&A 68: Can we de-risk anti-CD20 therapies?